The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study

REFERENCES

• Rog DJ, Nurmikko Tj, Friede T, Young CA. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology. 2005;65: 812–819.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639–645.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125–1132.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A, Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012; 184:1143–1150.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Jay CA, Shade SB, Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–521.
   PubMed Web of Science ®Google Scholar
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299–306.
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21–29.
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double blind, placebo-controlled clinical trial. Pain. 2007;133:210–220.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Tsodikov A, A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neurophatic pain. J Pain. 2008;9:506–521.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Deutsch R, Low-dose vaporized cannabis significantly improved neuropathic pain. J Pain. 2013;14:136–148.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro S, Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182:E694–E701.
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199–210.
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Wahlen A, Plasma delta-9 tetra-hydrocannabinol concetrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409–416.
   PubMed Web of Science ®Google Scholar
• Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Δ9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57:66–75.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chemistry and drug metabolism. Chem Biodivers. 2007;4:1770–1804.
   PubMed Web of Science ®Google Scholar
• Gieringer DH. Cannabis “vaporization”: a promising strategy for smoke harms reduction. J Cannabis Ther. 2001;1:153–170.
   Google Scholar
• Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;4:7–27.
   Google Scholar
• Abrams DI, Vizoso HP, Shade SB, Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007;82:572–578.
   PubMed Web of Science ®Google Scholar
• United Nations Office of Drugs and Crime. Recommended methods for the identification and analysis of cannabis and cannabis products. 2009. Available at: http://www.unodc.org/ documents/scientific/ST-NAR-40-Ebook.pdf. Accessed August 4, 2014.
   Google Scholar
• Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Media, PA: Williams and Wilkins; 1995.
   Google Scholar
• Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr. 1990;99:42–62.
   PubMedGoogle Scholar
• Fischedick J, Van Der Kobi F, Verpoorte R. Cannabinoid receptor 1 binding activity and quantitative analysis of cannabis sativa smoke and vapor. Chem Pharm Bull. 2010;58:201–207.
   PubMed Web of Science ®Google Scholar
• Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporized Cannabis sativa. Inhal Toxicol. 2009;21:1108–1112.
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Perry E, MacDougall L, The psychotomimetic effects of intravenous delta-9-tetrahy drocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572.
   PubMed Web of Science ®Google Scholar
• Hunault CC, Mensinga TT, de Vries I, Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl). 2008;201:171–181
   PubMed Web of Science ®Google Scholar
• Hunault CC, van Eijkeren JC, Mensinga TT, Disposition of smoked cannabis with high Δ9-tetrahydrocannabinol content: a kinetic model. Toxicol Appl Pharmacol. 2010;246:148–153.
   Google Scholar
• Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52:31–41.
   PubMed Web of Science ®Google Scholar
• Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and psychological effects and whole blood Δ9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012;36:405–412.
   PubMed Web of Science ®Google Scholar
• Desrosiers NA, Himes SK, Scheidweiler KB, Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60:631–643.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoids-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90:844–851.
   PubMed Web of Science ®Google Scholar
• Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR. Pharmacokinetic and pharmacodynamic profile of superatherapeutic oral doses of Δ9-tetrahydrocannabinol in cannabis users. J Clin Pharmacol. 2013;53:680–690.
   Google Scholar